Neuro-Oncology (journal)

New Statistical Report Reveals Primary Brain and Central Nervous System Tumors as Second Most Common Cancer Type in Adolescents and Young Adults

Retrieved on: 
Mardi, mai 7, 2024
CONNECT, Neuro-Oncology (journal), Brain, Adolescence, Bangladesh Technical Education Board, Survival, AYA, Partnership, National Cancer Institute, Research, History, CNS, Young adult, Disease, American Brain Tumor Association, Patient, Neurosurgery, NCI, ABTA, Neoplasm, Central nervous system, Biology, Clinical trial, Prevalence, Medical imaging

CHICAGO, May 7, 2024 /PRNewswire/ -- Today, the American Brain Tumor Association (ABTA), in partnership with the National Institutes of Health's National Cancer Institute (NCI) Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) program and the Central Brain Tumor Registry of the United States (CBTRUS), unveiled a new report shedding light on the prevalence of primary brain and other central nervous system (CNS) tumors among adolescents and young adults (AYAs) between the ages of 15 and 39. The report, Adolescent and Young Adult Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States, 2016–2020, published in Neuro-Oncology, aims to increase awareness of and insight into an underserved population with unique needs distinct from pediatric and older adult patient populations. 

Key Points: 
  • While cancer survival has been improving overall, adolescents and young adults between the ages of 15 and 39 have not experienced these same increases in survival.
  • The researchers found primary brain and other CNS tumors are the second most common cancer type in AYAs, with an average of 12,848 individuals diagnosed annually.
  • Over 90 percent survived for at least five years, with approximately 208,620 AYAs living with a history of brain or other CNS tumor diagnosis in 2024.
  • The ABTA is committed to ensuring the AYA brain tumor community has access to customized educational and emotional support resources to meet their unique needs.

Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

Retrieved on: 
Jeudi, avril 25, 2024
Neuro-Oncology (journal), University, University of Pennsylvania, Abstract, Survival, ICI, CADL, ASCO, Lung cancer, Dana–Farber Cancer Institute, Patient, Society, MPH, Harvard Medical School, Clinical trial, Annual general meeting, Associate, Therapy, NSCLC, Valaciclovir, Injection, Pharmaceutical industry

NEEDHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that two abstracts were accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 to June 4, 2024, in Chicago, IL.

Key Points: 
  • NEEDHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that two abstracts were accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 to June 4, 2024, in Chicago, IL.
  • The first presentation will feature data from the ongoing phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma.
  • Presenter: Charu Aggarwal, MD, MPH, Associate Professor for Lung Cancer Excellence, Perelman School of Medicine, University of Pennsylvania
    Full abstracts will be released by ASCO on Thursday, May 23, 2024, at 5:00 PM ET.
  • Details from the presentations will be available following the events on the Candel website at https://www.candeltx.com/media/ .

Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

Retrieved on: 
Mardi, avril 23, 2024
Neuro-Oncology (journal), First grade, FDA, Society, University, BRAF V600, Day One, Hospital, Acne, Safety, Food, Biopharmaceutical, Conference call, Nausea, Insurance, Conference, Research, Webcast, Viral, Speech, Fatigue, Human, Disease, BRAF, Vomiting, Patient, Medicine, Headache, Event, Rash, Constipation, Diagnosis, Head, Neoplasm, Upper respiratory tract infection, PRS, Xeroderma, Fever, Caregiver, Ageing, Pharmaceutical industry

BRISBANE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved OJEMDA (tovorafenib), a type II RAF inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. This indication is approved under accelerated approval based on response rate and duration of response. With the approval, Day One received a rare pediatric disease priority review voucher from the FDA.

Key Points: 
  • With the approval, Day One received a rare pediatric disease priority review voucher from the FDA.
  • “We are very proud that our first approved medicine addresses this serious and life-threatening disease of childhood and adolescence.
  • BRAF is the most commonly altered gene in pLGG, with up to 75 percent of children having a BRAF alteration.
  • “This is a tremendous moment not only for Day One, but also for the broader pediatric brain tumor community.

Gateway Celebrity Fight Night Celebrates 30th Anniversary Benefitting Early-Phase Cancer Research, Raising More Than $3 Million

Retrieved on: 
Mardi, avril 30, 2024
Emerald, Rhea, Neuro-Oncology (journal), FDA, University, Cancer, Minor planet, GRAMMY, Dallas Cowboys, Grammy Awards, Research, Life, Glioblastoma, NSYNC, Disease, Barrow Neurological Institute, Family, Mental health, Patient, FFF, Athlete, Mother, Memory, Diagnosis, Clinical trial, Division, Pharmaceutical industry

PHOENIX, April 30, 2024 /PRNewswire/ -- Gateway for Cancer Research—a nonprofit 501c(3) organization committed to funding innovative, Phase I and Phase II cancer trials — celebrated the 2024 Gateway Celebrity Fight Night 30th Anniversary, an Emerald Ball on Saturday, April 27 at the Fairmont Scottsdale Princess in Scottsdale, Arizona. More than $3 million was raised in a single night, and thanks to generous underwriting by Dr. Stacie J. and Mr. Richard J Stephenson, 100% of proceeds directly fund these early-phase clinical trials.

Key Points: 
  • Marking the gala's 30th anniversary in the Valley, 100% of proceeds from Gateway Celebrity Fight Night will directly fund early-phase cancer research.
  • PHOENIX, April 30, 2024 /PRNewswire/ -- Gateway for Cancer Research —a nonprofit 501c(3) organization committed to funding innovative, Phase I and Phase II cancer trials — celebrated the 2024 Gateway Celebrity Fight Night 30th Anniversary, an Emerald Ball on Saturday, April 27 at the Fairmont Scottsdale Princess in Scottsdale, Arizona.
  • Gateway Celebrity Fight Night drew actors, entertainers, athletes, philanthropists, and leading medical professionals to raise funds for early-phase cancer trials, as they are often overlooked and underfunded.
  • Mr. Stephenson is the founder of both Cancer Treatment Centers of America and Gateway for Cancer Research.

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

Retrieved on: 
Mercredi, avril 3, 2024
Harvard Medical School, Dana–Farber Cancer Institute, GBM, Code, Glioblastoma, Clinical trial, Society, Brigham and Women's Hospital, Hospital, Tokyo Stock Exchange, ASCO, Neuro-Oncology (journal), Annual general meeting

LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) has been selected for an oral presentation at the American Society of Clinical Oncology (2024 ASCO) Annual Meeting to be held May 31 – June 4, 2024 in Chicago.

Key Points: 
  • LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) has been selected for an oral presentation at the American Society of Clinical Oncology (2024 ASCO) Annual Meeting to be held May 31 – June 4, 2024 in Chicago.
  • The oral presentation will be presented by one of the investigators of this clinical trial, Gilbert Youssef, M.D., Attending Physician at Harvard Medical School, Center for Neuro-Oncology at Dana-Farber Cancer Institute and Brigham and Women's Hospital.
  • The presentation details are as follows:

Rady Children's Appoints Praveen Raju, MD, PhD, as the Nathan Gordon Chair and Medical Director of Neuro-Oncology Program

Retrieved on: 
Mardi, avril 2, 2024
Research, Diagnosis, Boston Children's Hospital, Brain, Health, Growth, Neurology, MSTP, Memory, Genetics, SAN, Patient, UC, Cancer, Medulloblastoma, Child, University, Neurosurgery, Doctor of Philosophy, Neuro, MD, Molecular biology, NIH, Laboratory, Pediatric neurosurgery, Neoplasm, Infant, Nathan Gordon, Hospital, Spinal cord, Pediatrics, Neuro-Oncology (journal), Medical director, Genetic distance, Nursing

At Rady Children's, Dr. Raju has also been named the Nathan Gordon Chair in Neuro-Oncology, established in 2021 to honor the memory of Nathan Gordon, who was diagnosed with a rare tumor in his spinal cord when he was just 15 months old.

Key Points: 
  • At Rady Children's, Dr. Raju has also been named the Nathan Gordon Chair in Neuro-Oncology, established in 2021 to honor the memory of Nathan Gordon, who was diagnosed with a rare tumor in his spinal cord when he was just 15 months old.
  • As part of Rady Children's nationally recognized care team, Dr. Raju will spearhead the growth of the Neuro-Oncology Program and advance research efforts on pediatric brain and spinal tumors.
  • By incorporating subspecialty expertise, Dr. Raju aims to address different forms of pediatric brain and spinal tumors.
  • By incorporating subspecialty expertise into the Neuro-Oncology Program, Dr. Raju aims to address the different forms and distinct molecular subtypes of pediatric brain and spinal tumors.

Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

Retrieved on: 
Jeudi, février 29, 2024
ONC201, MD, ASCO, Growth, Neuro-Oncology (journal), Manuscript, HGG, Conference, Human, Society, Patient, Journal, Survival, JCO, Pharmaceutical industry

DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2023 and provided an operational update.

Key Points: 
  • ET Today –
    DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2023 and provided an operational update.
  • Chimerix reported a net loss of $18.2 million, or $0.20 per basic and diluted share, for the fourth quarter of 2023, compared to a net loss of $21.0 million, or $0.24 per basic and diluted share for the fourth quarter of 2022.
  • General and administrative expenses decreased to $5.2 million for the fourth quarter of 2023, compared to $5.3 million for the same period in 2022.
  • Chimerix will host a conference call and live audio webcast to discuss fourth quarter and full-year 2023 financial results and provide a business update today at 8:30 a.m.

Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

Retrieved on: 
Vendredi, février 23, 2024
Type 1, DMG, NCT, CED, Neuro-Oncology (journal), Pons, Safety, Convection, Patient, Survival, Columbia University, Pharmaceutical industry

Nine patients were treated in the study (30 M group, n=3; 60 M group, n=4; 90 M group (optimal dose), n=2).

Key Points: 
  • Nine patients were treated in the study (30 M group, n=3; 60 M group, n=4; 90 M group (optimal dose), n=2).
  • Although the study was not powered to reliably demonstrate efficacy, median overall survival (OS) of patients in the study was 16.5 months.
  • This compares favourably with median survival rate in a cohort of 316 cases of 10.0 months (Jansen et al, 2015.
  • The results of the experiment were inconclusive in that they did not correlate with the results previously seen in in vitro and in vivo studies of tolimidone.

FRED’S TEAM SETS HISTORIC $8 MILLION FUNDRAISING RECORD FOR CANCER RESEARCH

Retrieved on: 
Mercredi, janvier 17, 2024
IDH, Brain, Patient, Glioma, Research, Berlin Marathon, MD, New York City Marathon, Life, Neuro, TCS, MSK, Neuro-Oncology (journal), Cancer, Nursing, Division, Running, Neurology, Pharmaceutical industry

New York, NY, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Fred’s Team, the official running program of Memorial Sloan Kettering Cancer Center (MSK), set a new single-season fundraising record in 2023 by raising $8 million for cancer research at MSK.

Key Points: 
  • New York, NY, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Fred’s Team, the official running program of Memorial Sloan Kettering Cancer Center (MSK), set a new single-season fundraising record in 2023 by raising $8 million for cancer research at MSK.
  • This new milestone is a testament to the Fred’s Team community’s enduring commitment to MSK’s mission of ending cancer for life.
  • Since 1995, Fred’s Team donors and participants have directed more than $112 million to MSK.
  • Fred’s Team participants get to choose the area of cancer research at MSK that they support with their miles.

Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

Retrieved on: 
Mercredi, décembre 13, 2023
Diamond, Patient, Conference, Lung cancer, AACR, Temozolomide, PR, Neoplasm, Diarrhea, EGFR, Dana–Farber Cancer Institute, Neuro-Oncology (journal), Brain, Therapy, Clinical trial, PD, Bevacizumab, CNS, Cancer, GBM, Diagnosis, Safety, PFS, NSCLC, Rash, Pharmaceutical industry

BDTX-1535, a fourth-generation, brain-penetrant, covalent EGFR inhibitor, is under investigation in a Phase 1 clinical trial for the treatment of patients with non-small cell lung cancer (NSCLC) or GBM.

Key Points: 
  • BDTX-1535, a fourth-generation, brain-penetrant, covalent EGFR inhibitor, is under investigation in a Phase 1 clinical trial for the treatment of patients with non-small cell lung cancer (NSCLC) or GBM.
  • Clinical data as of November 2023 reflect 27 patients with recurrent GBM who received a range of doses spanning 15mg to 400mg once daily (QD) in the dose escalation cohort.
  • Of the 27 patients with recurrent GBM, 22 were started at or escalated to a dose of 100mg QD or greater and reached at least one post baseline tumor assessment.
  • Black Diamond plans to submit results from the dose escalation GBM cohort for presentation at a medical meeting in the second quarter of 2024.